2 stories in this blend

Researchers utilized artificial intelligence to redesign key genetic sequences previously shown to reverse cellular damage in sight impaired mice. The computer generated gene variants achieved fifty times higher efficacy than the natural versions discovered over prior decades of manual biological research.

Pharmaceutical companies Merck and Moderna announced positive Phase 3 trial results for an individualized melanoma treatment designed with artificial intelligence. Algorithms examine each patient's blood and tumor mutations to target specific proteins, creating a tailored vaccine administered alongside standard immunotherapy.